AUR106 not checked

Aurigene Discovery Technologies Limited

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Relapse, Advanced Malignant Neoplasm, Non Small Cell Lung Cancer, Gastric Cancer, Urothelial Carcinoma, Kidney Cancer, Colon Cancer, Esophagus Cancer
Main trialPhase 1
“A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select Relapsed Advanced Malignancies (JIVAN).”In the company’s words, NCT05861947 on ClinicalTrials.gov

Other drugs for Relapse

All 268 drugs for Relapse

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Terminated 10 Feb 2026 A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow AUR106

Following is part of Solo: you see every change to AUR106 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in